Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1Diabetes Mellitus 1

Interventions

Pioglitazone 3Surveys and Questionnaires 2Specimen Handling 2Glucose Tolerance Test 2Biopsy 2pembrolizumab 1nabiximols 1Urine Specimen Collection 1Testosterone 1Standard of Care 1Phlebotomy 1Liquid Biopsy 1Interviews as Topic 1Hypoglycemic Agents 1Gonadotropin-Releasing Hormone 1Gastrectomy 1Endoscopic Mucosal Resection 1Electrocardiography 1Eating 1DNA 1Clinical Laboratory Techniques 1Cari-D-Tect 1Blood Specimen Collection 1Becaplermin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Diabetes Mellitus × Becaplermin × Clear all
NCT00518102 2016-07-19

The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])

Ethicon, Inc.

Completed
4,431 enrolled

Diabetes Mellitus, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡